Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,170 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Central Nervous System Embryonal Tumor Clear all
Active, not recruiting Early Phase 1 Interventional

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

NCT05634707
View directory record Official record
Conditions
Primary Brain Tumor, Brain Tumor, Recurrent
Interventions
Fluoxetine, Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
24 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Diego, California • Stanford, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas

NCT00095771
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
3 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

NCT02271711
View directory record Official record
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
Interventions
Laboratory Biomarker Analysis, Natural Killer Cell Therapy
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 23, 2026, 4:19 PM EDT
Recruiting Phase 2 Interventional

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

NCT06368817
View directory record Official record
Conditions
Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
Interventions
3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

NCT06389591
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00082797
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
leucovorin calcium, methotrexate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
65
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 23, 2026, 4:19 PM EDT
Recruiting Phase 2 Interventional

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT07326566
View directory record Official record
Conditions
Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions
silevertinib in combination with temozolomide, temozolomide (TMZ)
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

NCT00089427
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
Interventions
IL13-PE38QQR, Surgery for placement, Radiation therapy, Temozolomide with radiation therapy
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
San Francisco, California • Charlotte, North Carolina • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Sep 23, 2026, 4:19 PM EDT
Active, not recruiting Phase 1 Interventional

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686
View directory record Official record
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional

A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer

NCT00754286
View directory record Official record
Conditions
Brain Tumors, Leukemia, Sarcomas, Neuroblastoma, Lymphoma, Hodgkins Disease
Interventions
Aromatherapy Scented Wand, Placebo wand
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
7 Years to 21 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 23, 2026, 4:19 PM EDT
Suspended Phase 1Phase 2 Interventional

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT06329570
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue
Interventions
NaviFUS System, Lumason, Bevacizumab
Device · Drug
Lead sponsor
NaviFUS Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

NCT00003173
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Retinoblastoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

NCT01977677
View directory record Official record
Conditions
Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglial Tumors, Adult Pineoblastoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
Interventions
radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study
Radiation · Drug · Other
Lead sponsor
Lawrence Recht
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

NCT01120639
View directory record Official record
Conditions
Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
Interventions
Temozolomide, Stereotactic Radiosurgery (SRS)
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 23, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 23, 2026, 4:19 PM EDT
Withdrawn Not applicable Interventional

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

NCT02309632
View directory record Official record
Conditions
Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions
Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas

NCT00002753
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
iodine I 131 monoclonal antibody 81C6
Radiation
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas

NCT00612339
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Avastin and Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 23, 2026, 4:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

NCT05588453
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Natural Killer Cell Therapy, Temozolomide
Biological · Drug
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534
View directory record Official record
Conditions
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
palifosfamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 23, 2026, 4:19 PM EDT
Terminated Phase 1 Interventional

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

NCT00227032
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).

NCT01688401
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions
Melphalan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Month to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 23, 2026, 4:19 PM EDT
Not listed Phase 1Phase 2 Interventional

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

NCT00275067
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 23, 2026, 4:19 PM EDT